Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. ICLR
4. LAES
5. JPM
6. DRI
7. SPY
8. FUL
9. IONS
10. IBM

Go back to Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

Cowen Sees Favorable Risk/Reward in Endocyte (ECYT) Amid Phase III Trial of PSMA-617

February 27, 2018 3:33 PM EST

Endocyte, Inc. (NASDAQ: ECYT) recently announced that the commencement of a pivotal Phase III trial of its leading drug, PSMA-617, a radioligand therapeutic that targets the prostate-specific membrane antigen. This announcement, coming alongside the company's 4Q earnings, has prompted analysts at Cowen to... More